Is It Too Late to Buy AbbVie Stock?
Past performance isn't a guarantee of future success, and that's as true in life as it is in the stock market. But past performance isn't meaningless either; investing in a company capable of replicating a winning strategy is a pretty good bet. With that in mind, let's look at pharma giant AbbVie (NYSE: ABBV).
Unlike most of its peers in the pharmaceutical industry, this drugmaker has outperformed the broader market in the past nine years. The bears will point to declining sales of AbbVie's rheumatoid arthritis drug Humira in Europe as evidence that its growth days are well behind it.
Yet there is much more to the story than that. Let's consider whether it's still worth purchasing AbbVie's shares today.
Source Fool.com
